Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 3/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | RORC | P51449 | 2/20 | 0.40 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.39 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2112991 | 1.00 | NR1H2 (0.46) | NR1H2SLC6A2SLC6A4SLC6A3MGLL | |
| SCHEMBL2275445 | 0.90 | USP30 (0.51) | SLC6A2SLC6A4SLC6A3USP30GPR119 | |
| SCHEMBL22031700 | 0.85 | NR1H2 (0.50) | NR1H2USP30JAK2JAK1GPR119 | |
| SCHEMBL15637939 | 0.84 | USP30 (0.55) | USP30GPR119 | |
| SCHEMBL29577158 | 0.84 | USP30 (0.55) | USP30GPR119 | |
| SCHEMBL30740748 | 0.83 | GPR119 (0.55) | USP30GPR119 | |
| SCHEMBL1364255 | 0.83 | GPR119 (0.55) | USP30GPR119 | |
| SCHEMBL16242384 | 0.83 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3MGLLFAAH | |
| SCHEMBL15640904 | 0.83 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3MGLLFAAH | |
| SCHEMBL15640905 | 0.83 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3MGLLFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697883-B2 | Cyclopenta[C]pyrrole-2-carboxylate derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-04-15 | — | — | US | disclosed |
| US-20120095040-A1 | CYCLOPENTA[C]PYRROLE-2-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095040-A1 | CYCLOPENTA[C]PYRROLE-2-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | EPOR, ACAD9, CBR1 | NR1H2 997/4885SLC6A2 1817/4885SLC6A4 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.